Overall Adverse Event Rates Dose Group Any Adverse Event (%) GI Adverse Events (%) Discontinuation Due to AE (%) Placebo 72.1% 32.6% 0% 1 mg 88.6% 48.6% 2.9% 4 mg (escalated) 88.6% 60.0% 5.7% 4 mg (single dose) 90.9% 63.6% 6.1% 8 mg (escalated) 87.5% 57.5% 5.0% 8 mg (single dose) 88.6% 62.9% 5.7% 12 mg (escalated) 97.2% 66.7% 8.3% Source: Jastreboff AM, Kaplan LM, Fras JP, et al

Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School BRAIN-TO Lab, Techna Institute, University Health Network Brigham and Womens Hospital Brigham and Womens Hospital, Harvard Medical School Brigham and Women's Hospital Brigham and Women's Hospital , Harvard Medical School Brigham and Women's Hospital , Harvard Medical School, Brigham and Women's Hospital / Harvard Medical School Brigham and Women's Hospital, Harvard Medical School Brigham and Women's Hospital/Harvard Medical School Brigham and Women's Hospital/Harvard University Brigham Young University Brighams and Women Hospital Brighton and Sussex Medical School Brighton BodyTalk Bristol Myers Squibb British Columbia Cancer Research Centre Brno University of Technology Brno University of Technology, Faculty of Electrical Engineering and Communication Brown University Bruker BioSpin MRI GmbH Bruker Japan K.K

RaFoSA: random forests secondary structure assignment for coarse-grained and all-atom protein systems
To maintain freshness and efficacy of our products, store them in a cool, dry place away from direct sunlight and moisture